DUBLIN – Shares in Morphosys AG (NASDAQ:MOR) closed at $28 Monday, 6.6 percent below Friday's closing price, on news that it lost a long-running patent dispute over CD38-directed antibodies against Genmab A/S and Johnson & Johnson Co. Genmab A/S's stock (Copenhagen:GEN), in contrast, opened Monday 3.5 percent higher, and ended the day at DKK$974.20 (US$149.11). Investors on each side appear to have concluded that Morphosys' chances of getting a slice of Genmab's lucrative royalty payments have evaporated.